Toll-like receptor 3: a double-edged sword by Marvin L Hsieh, Daisuke Nishizaki, Jacob J Adashek, Shumei Kato, Razelle Kurzrock

Get full text

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy by Razelle Kurzrock, Ryosuke Okamura, Shumei Kato, Suzanna Lee, Rebecca E Jimenez, Jason K Sicklick

Get full text

ICOS and ICOS ligand: expression patterns and outcomes in oncology patients by Mina Nikanjam, Shumei Kato, Daisuke Nishizaki, Donald A. Barkauskas, Sarabjot Pabla, Mary K. Nesline, Jeffrey M. Conroy, Aung Naing, Razelle Kurzrock

Get full text

4‐1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4‐1BB agonists by Yuji Uehara, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary K. Nesline, Sarabjot Pabla, Jeffrey M. Conroy, Paul DePietro, Heidi Ko, Jason K. Sicklick, Razelle Kurzrock

Get full text

Gene- and immune-targeted therapy combinations using dual-matched biomarkers for patient selection by Daisuke Nishizaki, Razelle Kurzrock, Jacob J. Adashek, Ki Hwan Kim, Hyo Jeong Lim, Mina Nikanjam, Ramez N. Eskander, Paul T. Fanta, Ryosuke Okamura, Suzanna Lee, Jason K. Sicklick, Scott M. Lippman, Shumei Kato

Get full text